[Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy].
A free radical scavenger Edaravone is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Of great importance for regenerative therapy and gene therapy are the neural stem cells which are intrinsically activated or exogenously transplanted. Addition of NTFs greatly enhanced an intrinsic migration or invasion of stem cells into the scaffold, which could provide a future regenerative potential against ischemic brain damage at chronic stage.
Abe
Koji
K
Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University.
D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D004359:Drug Therapy, Combination; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D015316:Genetic Therapy; D006801:Humans; D044968:Regenerative Medicine; D020521:Stroke / Q000628:therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D016166:Free Radical Scavengers; D010959:Tissue Plasminogen Activator; D000077553:Edaravone; D000983:Antipyrine